Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes
NCT ID: NCT03829800
Last Updated: 2019-02-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2016-09-01
2018-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Response of Slow Released Carbohydrates in Diabetes Mellitus
NCT01070238
Sucralose in Subjects With Diabetes Mellitus Insulin Requesting
NCT02813759
Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas
NCT00540488
Effects of Artificial Sweeteners on Glucose Metabolism in Patients With Type 2 Diabetes
NCT04185662
Effects of Sucralose on Glucose Metabolism
NCT02589002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ensure® Abbott Nutrition
A standard nutritional formula not specific for diabetics
Ensure® Abbott Nutrition
Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Glucerna® Abbott Nutrition
A formula with a patented blend of slow-digesting carbohydrates including resistant maltodextrin and sucromalt
Glucerna® Abbott Nutrition
Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Diasip® Nutricia Advanced
A formula whose composition has isomaltulose and resistant starch
Diasip® Nutricia Advanced
Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Glicolab®
Glucose solution
Glicolab®
Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ensure® Abbott Nutrition
Effect of the intake of Ensure® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Glucerna® Abbott Nutrition
Effect of the intake of Glucerna® Abbott Nutrition on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Diasip® Nutricia Advanced
Effect of the intake of Diasip® Nutricia Advanced on the glycemic index, insulin, GLP-1, GIP levels and subjective appetite in subjects with type 2 diabetes
Glicolab®
Effect of the intake of Glicolab on the glycemic index, insulin and subjective appetite in subjects with type 2 diabetes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Demonstrated use of oral hypoglycemic agents (metformin), for at least two months
* BMI of 18.5 kg/m2 to ≤ 35 kg/m2
Exclusion Criteria
* Diabetic ketoacidosis
* Congestive heart failure
* Gastric, renal or hepatic diseases
* Myocardial infarction
* Stroke
* Subjects with insulin therapy, antibiotic therapy or corticosteroids
* End-stage organ failure
* Individuals with organ transplantation
* Coagulation or bleeding disorder
* Infectious or chronic contagious disease (such as tuberculosis, hepatitis B or C or HIV).
51 Years
63 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad del Zulia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel J Aparicio Camargo
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lisse Angarita, PhD
Role: PRINCIPAL_INVESTIGATOR
Universidad Andrés Bello, Facultad de Medicina - Sede Concepción
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1001092016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.